Email this article Prolonged bone marrow aplasias in patients with acute leukemias after chemotherapy
- Authors: Gaidamaka NV1, Parovichnikova EN1, Zavalishina LE2, Garmayeva TT.1, Gaponova TV1, Troitskaya VV1, Pokrovskaya OS1, Tikhomirov DS1, Khodunova EE1, Maryin DS1, Kaplanskaya IB1, Ustinova EN1, Mikhailova EA1, Isayev VG1, Gribanova EO1, Savchenko VG1
-
Affiliations:
- Hematology Research Center, Russian Academy of Medical Sciences, Moscow
- P. A. Herzen Moscow Oncology Research Institute
- Issue: Vol 82, No 7 (2010)
- Pages: 29-34
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30611
- ID: 30611
Cite item
Full Text
Abstract
Materials and methods. Data on 7 patients with acute myeloid leukemia, followed up at the Hematology Departments, Hematology Research Center, Russian Academy of Medical Sciences, over the period 2003 to 2007, who had developed deep bone marrow aplasia (BMA) inadequate to cytostatic drug exposure during chemotherapy, were analyzed. The authors compared in all the patients the values of peripheral blood and bone marrow (BM) puncture specimens and the results of blood tests using the polymerase chain reaction at different AL development stages with the results of an immunohistochemical study using the markers of viruses of hepatitis C and B, a herpes group (EBV, CMV, HSV-1, HSV-2) and parvovirus B19.
Results. The marker of hepatitis C was detected in 6 of the 7 patients with prolonged BMA; 3 of these 6 patients showed a simultaneous infection with hepatitis B. Six of the 7 patients were found to have concomitant BM lesion with various herpes group viruses. Two patients had a resistant form of AL.
Conclusion. Hepatitis C virus infection in patients and the resistant form of the disease were the principal causes of the development of BMA inadequate to cytostatic drug exposure. Affliction of abundant bone marrow cells with herpes group viruses was not a direct cause, but might substantially aggravate BMA.
Keywords
About the authors
N V Gaidamaka
Hematology Research Center, Russian Academy of Medical Sciences, Moscow
Email: nadya314@yandex.ru
Hematology Research Center, Russian Academy of Medical Sciences, Moscow
E N Parovichnikova
Hematology Research Center, Russian Academy of Medical Sciences, Moscow
Email: elenap@blood.ru
Hematology Research Center, Russian Academy of Medical Sciences, Moscow
L E Zavalishina
P. A. Herzen Moscow Oncology Research InstituteP. A. Herzen Moscow Oncology Research Institute
T Ts Garmayeva
Hematology Research Center, Russian Academy of Medical Sciences, Moscow
Email: garmaeva@yandex.ru
Hematology Research Center, Russian Academy of Medical Sciences, Moscow
T V Gaponova
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
V V Troitskaya
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
O S Pokrovskaya
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
D S Tikhomirov
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
E E Khodunova
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
D S Maryin
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
I B Kaplanskaya
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
E N Ustinova
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
E A Mikhailova
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
V G Isayev
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
E O Gribanova
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
V G Savchenko
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
References
- Воробьев А. И. Руководство по гематологии. М.: Изд-во "Ньюдиамед"; 2002; т. 1: 175-250.
- Bernard J. Anemia, leucopenia, thrombopenia, caused by drugs. Presse Med. 1962; 70: 531-533.
- Bernard J., Boiron M., Weil M. et al. Study of the complete remission of acute leukemia. (Analysis of 300 cases). Nouv. Rev. Fr. Hematol. 1962; 2: 195-222.
- Islam A. Pattern of bone marrow regeneration following chemotherapy for acute myeloid leukemia. J. Med. 1987; 18: 108-122.
- Wilkins B. S., Bostanci A. G., Ryan M. F. et al. Haemopoietic regrowth after chemotherapy for acute leukemia: an immunohistochemical study of bone marrow trephine biopsy specimens. J. Clin. Pathol. 1993; 46 (10): 915-921.
- Савченко В. Г. Программное лечение лейкозов. М.; 2008; т. 1.
- Хохлова М. П. Острый лейкоз (патологическая анатомия и некоторые вопросы патогенеза): Дис. ... д-ра мед. наук. М.; 1965.
- Алексеев Н. А. Анемии. СПб.: Гиппократ; 2004. 466-474.
- Михайлова Е. А., Ядрихинская В. Н., Савченко В. Г. Апластические анемии и вирусные гепатиты (постгепатитные апластические анемии). Тер. арх. 1999; 7: 64-69.
- Safadi R., Or R., Ilan Y. et al. Lack of known hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone marrow transplantation. Bone Marrow Transplant. 2001; 27: 183-190.
- Alliot C., Barrios M., Taib J. et al. Parvovirus B19 infection in an HIV-infected patient with febrile pancytopenia and acute hepatitis. Eur. J. Clin. Microbiol. Infect. Dis. 2001; 20 (1): 43-44.
- Almedia-Porada G. D., Ascensao J. L. Cytomegalovirus as a cause of pancytopenia. Leukemia and Lymphoma 1996; 21 (3-4): 217-223.
- Jordheim L. P., Nguyen-Dumont T., Thomas X. et al. Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53. Drug Metab. Dispos. 2008; 36 (12): 2419-2423.
- Mansson E., Flordal E., Liliemark J. et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem. Pharmacol. 2003; 65 (2): 237-247.
- Carlo-Stella C., Tabilio A., Regazzi E. et al. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors. Bone Marrow Transplant. 1997; 20: 465-471.
- Cheson B. D., Bennett J. M., Kopecky K. J. et al. Revised recommendation of international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J. Clin. Oncol. 2003; 21 (24): 4642-4649.
- Гармаева Т. Ц., Куликов С. М., Михайлова Е. А. и др. Клинико-эпидемиологическая характеристика инфицированности вирусами гепатитов В и С больных с заболеваниями системы крови при поступлении в стационар. Гематол. и трансфузиол. 2009; 54 (1): 3-9.
Supplementary files
